3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

With stock market risks emerging, is now the time to consider the 60/40 portfolio?

The stock market could be in for a period of turbulence. Here’s a simple strategy that can help long-term investors…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Is a stock market crash coming? It’s not too late to get ready!

Christopher Ruane sees reasons to fear a coming stock market crash. Rather than tying to time it, he's hoping to…

Read more »

Investing Articles

Down 4% in 2026, is now the time to consider buying Nvidia shares

Has Nvidia become too big to keep growing? Or is the stock’s decline this year a chance to think about…

Read more »

Investing Articles

Is the party finally over for Rolls-Royce shares?

Rolls-Royce shares have made investors rich but momentum is slowing and the Iran conflict isn't helping. How worried should we…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

7.8% dividend yield! A dirt-cheap UK income share to buy today?

I’m on the hunt for lucrative passive income opportunities, and this under-the-radar FTSE stock currently offers a whopping 7.8% dividend…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

3 passive income stocks tipped to soar 41% (or more) by 2027

One of these shares offering passive income is trading at a massive 79% discount to where City analysts think it…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

171,885 shares of this FTSE dividend star pays an income equal to the State Pension

Zaven Boyrazian calculates how many shares investors would have to buy to generate enough income to match the UK State…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

This stock’s the opposite of red-hot at the moment. But I reckon it could still be one to buy

The recent dramatic fall in the value of this FTSE 100 stock makes James Beard think it’s a stock to…

Read more »